Universal Aspirin in High-Risk Pregnancies?
-
By
February 11, 2026
-
3 min
A recent cohort study presented at the Society for Maternal-Fetal Medicine 2026 Pregnancy Meeting suggests that universal aspirin dispensation at the first prenatal visit can reduce the rate of preeclampsia with severe features by 29% in high-risk populations. Following the implementation of daily 162 mg aspirin for patients under 16 weeks' gestation at a Dallas public hospital in August 2022, rates of severe preeclampsia and gestational hypertension decreased. The study noted a decline in postpartum hemorrhage and stable rates for placental abruption. Despite limitations in generalizing findings, researchers noted no harm from aspirin use, indicating a potential for improved prenatal care strategies.
1. Aspirin reduces preeclampsia rates by 29%. 2. Daily intake is 162 mg for high-risk pregnancies. 3. Implementation began August 3, 2022. 4. Postpartum hemorrhage rates decreased from 9.5% to 8.9%. 5. The study focused on a predominantly Hispanic population. 6. No significant harm from aspirin was reported. 7. Findings are observational and may not generalize to all populations.
Listen Tab content
